Processing your payment...
Please do not close your browser.

Insulin API Market- Global Growth, Trends and Forecast (2022 - 2029) By Type (Regular Human Insulin, Insulin Analogue, Others), By End-user (Fast-acting, Long-acting, Premix) and By Regions

12 Jul, 2022 | 159 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Insulin API Market will register a CAGR of 5.4 % in terms of revenue and the global market size will reach USD xx Billion by 2029.

Insulin API Market Overview

Insulin is a crucial medication used to treat patients with diabetes. It is used to treat people with both type 1 and type 2 diabetes, where type 1 diabetes is a disease in which the body does not produce insulin, and type 2 diabetes is brought on by the body's inability to effectively utilize insulin, which leads in an inability to manage blood sugar levels. According to BMJ Global Health, around 100 million individuals globally use insulin in 2018. The primary reasons predicted to contribute to the growth of the insulin API market are the increased manufacturing of insulin to satisfy the demand of diabetics and a rise in product development.

The market is expected to be driven in the upcoming years by the growing incidence of diabetes among the population worldwide. For instance, diabetes prevalence has been increasing more quickly in low- and middle-income nations, where it is the sixth-largest cause of death, according to the WHO. About 1.5 million people died from diabetes in 2019. A variety of innovative biologics, as well as reasonably priced recombinant human insulin and insulin analogs, have been successfully brought to market by the Biocon Company.

What is our Insulin API Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 5.4 % during the review period (2022 to 2029).

 

By Type

  • Regular Human Insulin
  • Insulin Analogue
  • Others 

By End-User

  • Fast-acting
  • Long-acting
  • Premix

 

 

By Companies

  • Novo Nordisk A/S
  • Biocon
  • Julphar
  • Torrent Pharmaceuticals Ltd.
  • Eli Lilly and Company.
  • Tonghua Dongbao
  • Ganlee

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

159

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Insulin API Market during the forecast period (2022-2029)?

The Insulin API Market is growing at a CAGR of 5.4 % over the next 7 years.

Who are the key players in Insulin API Market?

Novo Nordisk A/S, Biocon, Julphar, Torrent Pharmaceuticals Ltd., Eli Lilly and Company., Tonghua Dongbao, Ganlee, Others.

What region does this Insulin API Market report cover?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What is the significant Type of Insulin API Market?

Regular Human Insulin, Insulin Analogue, Others.

What is the significant End User of the Insulin API Market?

Fast-acting, Long-acting, Premix.

Who are the Major Players in Insulin API Market?

Market Growth Reports lists out all the Insulin API Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Novo Nordisk A/S, Biocon, Julphar, Torrent Pharmaceuticals Ltd., Eli Lilly and Company., Tonghua Dongbao, Ganlee, Others  

Industry News:

In February 2020, Sanofi to produce and commercialize active pharmaceutical ingredients (API), which are the essential molecules needed to make up any medicine and are responsible for its beneficial effects, Sanofi intends to establish a significant, leading European firm.

In February 2021, the International Diabetes Federation (IDF) and Biocon Biologics Ltd. have teamed up as the first biosimilar insulins firm to promote and support the IDF's Core Mission concept and activities. Biocon Biologics Ltd.

What are the major Types and End Users for Insulin API Market?

By Type, it is segmented into

  • Regular Human Insulin
  • Insulin Analogue
  • Others

By End User, it is segmented into

  • Fast-acting
  • Long-acting
  • Premix

Insulin API Market Regional Analysis

The Insulin API market may be segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America is anticipated to control the market, and it is anticipated that it will continue to do so throughout the projected period. factors like diabetes' rising incidence in North America. According to the American Diabetes Association, 34.2 million Americans, or over 10.5 percent of the population, had diabetes in 2018. Additionally, the market is expanding due to the spike in demand for generic insulin. The market in Europe is influenced by things like the big firms' growing client bases and commercial operations.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL INSULIN API MARKET BY TYPE
    3. GLOBAL INSULIN API MARKET BY END-USER
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST OF MATERIALS
    3. OPPORTUNITIES
      1. INSULIN API MARKET GROWTH
    4. APPLICATION OF INSULIN API MARKET IMPACT OF COVID 19
  5. GLOBAL INSULIN API MARKET, BY TYPE
    1. INTRODUCTION
    2. REGULAR HUMAN INSULIN
    3. INSULIN ANALOGUE
    4. OTHERS
  6. GLOBAL INSULIN API MARKET, BY END-USER
    1. INTRODUCTION
    2. FAST-ACTING
    3. LONG-ACTING
    4. PREMIX
  7. GLOBAL INSULIN API MARKET, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  8. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  9. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
      1. NOVO NORDISK A/S
      2. BIOCON
      3. JULPHAR
      4. TORRENT PHARMACEUTICALS LTD.
      5. ELI LILLY AND COMPANY.
      6. TONGHUA DONGBAO
      7. GANLEE

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla